Shaanxi Cuikang Pharmaceutical Technology Co., Ltd

Abiolone is only approved for the treatment of paclitaxel chemotherapy refractory CPRC. However, a better understanding of its active mechanism and tolerable adverse reactions is essential for its wider clinical application. Ryan et al. analyzed the data in the interim of the cOuAA-302 study, and showed that in this study, 1088 patients with metastatic CPRC who had not received chemotherapy were treated with abiolone acetate combined with prednisone. The main observation indicators were the overall survival rate and imaging indicators. The experiment confirmed that in an average of 8 months, compared with the control group, abiolone combined with prednisone slowed the spread of cancer and delayed the chemotherapy time from 16.8 months to 25.